BRIEF—Eisai divests future economic rights for elacestrant

Japanese drugmaker Eisai has entered into an agreement to transfer all future economic rights for elacestrant, approved for the treatment for breast cancer in the USA, to Canada-headquartered DRI Healthcare Trust.

Elacestrant is a selective estrogen receptor degrader discovered by Eisai.

In 2006, Eisai granted Radius Health an exclusive worldwide license (with Japan included in 2015) concerning the research, development, manufacture and marketing of the given compound and, in return, had the rights to receive certain financial payments, including milestones, and royalties on net sales of elacestrant, etc.

In this agreement with DRI Healthcare, Eisai transfers to DRI Healthcare all of its future economic rights. Eisai will receive an upfront payment of $85 million for the transfer.

As a result of this transaction, Eisai anticipates no changes to its consolidated financial forecast for the period ended March 31, 2024.